R&D Innovation
The company’s R&D team was founded in 2002 and has grown to a core team consisting of nearly 200 professional researchers, including numerous senior scientists with over 10 years of experience in pharmaceutical R&D.
The R&D center is equipped with many internationally advanced production equipment and technologies that constitute a complete system for new drug R&D projects. After years of efforts, this system has transformed into an all-round scientific research system encompassing information research and survey, product project establishment, chemical synthesis, quality research, formulation research, and pilot scale production.
-
R&D team was Established in
2002 -
Professional researchers
200 -
Drug development experience of core members
10years
Currently, the company has established three R&D technological platforms, namely the “new injection process platform” “large compound formulation platform” “new lyophilization platform” Furthermore, its R&D platforms are extending to cover oral solid formation and new drug delivery system.
New injection process platform
Large compound formulation platform
New lyophilization platform
The R&D center is equipped with hundreds of pharmaceutical R&D instruments, such as high performance liquid chromatography system, ultra high performance liquid chromatography, gas chromatograph, inductively coupled plasma emission spectrometer, inductively coupled plasma emission mass spectrometer, high performance liquid chromatography-mass spectrometry system, amino acid analyzer, ion chromatography system, ultraviolet spectrophotometer, drug stability testing chamber, freeze dryer, insoluble particle detector, one millionth of a balance, PH meter, muffle furnace, and various other experimental equipment necessary for synthesis.
Leveraging its own technological advantages and guided by clinical and market demands, Weixinkang is focused on the R&D of drug products with high market demand, high technological requirement and low competition. The company adheres to a step-wise R&D strategy of “one pipeline for marketing, one for backup, one under research, and one for project establishment.” The company has obtained 14 invention patents during its independent R&D. Since 2015, Weixinkang has obtained 17 new drug certificates and 17 registration approvals for 12 drug products. In addition, the company has over 30 R&D projects and many projects under registration review and approval. After years of unremitting innovation, the company has gained obvious competitive edges in various fields of expertise and developed and cultivated a series of superior products with clear clinical efficacy and promising market prospects that filled market gaps in China.
